<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Scisparc Ltd — News on 6ix</title>
    <link>https://6ix.com/company/scisparc-ltd</link>
    <description>Latest news and press releases for Scisparc Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 16 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/scisparc-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c31a78dffbe2df1199cd.webp</url>
      <title>Scisparc Ltd</title>
      <link>https://6ix.com/company/scisparc-ltd</link>
    </image>
    <item>
      <title>SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-clearmind-medicine-collaboration-leads-to-patent-application-for-depression-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-clearmind-medicine-collaboration-leads-to-patent-application-for-depression-therapy</guid>
      <pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
      <description>TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV:</description>
    </item>
    <item>
      <title>Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy</title>
      <link>https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-announces-hong-kong-patent-filing-for-depression-therapy-120</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-announces-hong-kong-patent-filing-for-depression-therapy-120</guid>
      <pubDate>Fri, 13 Mar 2026 11:45:00 GMT</pubDate>
      <description>Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030 Vancouver, Canada, March 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major und</description>
    </item>
    <item>
      <title>SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-3</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-announces-publication-of-international-patent-in-collaboration-with-clearmind-medicine-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-3</guid>
      <pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
      <description>TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV:</description>
    </item>
    <item>
      <title>Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease</title>
      <link>https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-announces-publication-of-international-patent-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-6</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-announces-publication-of-international-patent-for-novel-therapy-targeting-weight-loss-and-fatty-liver-disease-6</guid>
      <pubDate>Tue, 10 Mar 2026 12:59:00 GMT</pubDate>
      <description>Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation</description>
    </item>
    <item>
      <title>SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-subsidiary-neurothera-labs-75percent-signs-definitive-agreement-to-acquire-majority-stake-in-cliniquantum-innovator-in-quantum-based-clinical-trails</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-subsidiary-neurothera-labs-75percent-signs-definitive-agreement-to-acquire-majority-stake-in-cliniquantum-innovator-in-quantum-based-clinical-trails</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV:</description>
    </item>
    <item>
      <title>SciSparc Announces 1-for-9 Reverse Share Split</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-announces-1-for-9-reverse-share-split</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-announces-1-for-9-reverse-share-split</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held</description>
    </item>
    <item>
      <title>SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-granted-u-132400312</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-granted-u-132400312</guid>
      <pubDate>Mon, 02 Feb 2026 13:24:00 GMT</pubDate>
      <description>NeuroThera’s Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the U</description>
    </item>
    <item>
      <title>SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-successfully-completes-acquisition-ip-131300007</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-successfully-completes-acquisition-ip-131300007</guid>
      <pubDate>Mon, 26 Jan 2026 13:13:00 GMT</pubDate>
      <description>SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including th</description>
    </item>
    <item>
      <title>SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-signs-definitive-agreement-acquire-115500680</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-signs-definitive-agreement-acquire-115500680</guid>
      <pubDate>Tue, 13 Jan 2026 11:55:00 GMT</pubDate>
      <description>SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing TEL AVIV, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the signing of a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovati</description>
    </item>
    <item>
      <title>SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-announces-receipt-nasdaq-notification-210200972</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-announces-receipt-nasdaq-notification-210200972</guid>
      <pubDate>Mon, 12 Jan 2026 21:02:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the “Notification Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requi</description>
    </item>
    <item>
      <title>SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-granted-patent-131700771</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-granted-patent-131700771</guid>
      <pubDate>Tue, 30 Dec 2025 13:17:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This p</description>
    </item>
    <item>
      <title>IM Cannabis Appoints Asi Levi as Chief Financial Officer</title>
      <link>https://6ix.com/company/scisparc-ltd/news/im-cannabis-appoints-asi-levi-as-chief-financial-officer-2</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/im-cannabis-appoints-asi-levi-as-chief-financial-officer-2</guid>
      <pubDate>Fri, 12 Dec 2025 21:01:00 GMT</pubDate>
      <description>IM Cannabis Corp. (&quot;IMC&quot; or the &quot;Company&quot;) (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company&apos;s Chief Financial Officer (&quot;CFO&quot;), effective immediately, to replace Uri Birenberg.</description>
    </item>
    <item>
      <title>SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-signs-non-142900941</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-signs-non-142900941</guid>
      <pubDate>Tue, 02 Dec 2025 14:29:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a non-binding term sheet (the “Term Sheet”) with an Israeli-based pioneering quantum computing bio data company focuse</description>
    </item>
    <item>
      <title>SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-plans-entering-multi-billion-133200310</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-plans-entering-multi-billion-133200310</guid>
      <pubDate>Mon, 01 Dec 2025 13:32:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., recently announced the signing of a binding term sheet to acquire treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. (&quot;Xylo”). The MUSE™ system</description>
    </item>
    <item>
      <title>SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-acquire-treasury-patents-innovative-123800285</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-acquire-treasury-patents-innovative-123800285</guid>
      <pubDate>Wed, 26 Nov 2025 12:38:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., today announced the signing of a binding term sheet to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. (&quot;Xylo”). The MUSE™ system</description>
    </item>
    <item>
      <title>SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-announces-israeli-114200006</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-neurothera-labs-announces-israeli-114200006</guid>
      <pubDate>Thu, 20 Nov 2025 11:42:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (&quot;NeuroThera&quot;), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. by filing an Israeli patent application for an innovative combination</description>
    </item>
    <item>
      <title>Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression</title>
      <link>https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-files-israeli-patent-for-novel-non-hallucinogenic-neuroplastogen-treatment-for-depression</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/clearmind-medicine-files-israeli-patent-for-novel-non-hallucinogenic-neuroplastogen-treatment-for-depression</guid>
      <pubDate>Mon, 17 Nov 2025 12:55:00 GMT</pubDate>
      <description>Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &quot;Company&quot;), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing</description>
    </item>
    <item>
      <title>N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers</title>
      <link>https://6ix.com/company/scisparc-ltd/news/n2off-completed-merger-with-cancer-drug-discovery-company-targeting-tough-to-treat-pancreatic-and-lung-cancers</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/n2off-completed-merger-with-cancer-drug-discovery-company-targeting-tough-to-treat-pancreatic-and-lung-cancers</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy</description>
    </item>
    <item>
      <title>SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-announces-closing-acquisition-publicly-115500708</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-announces-closing-acquisition-publicly-115500708</guid>
      <pubDate>Fri, 24 Oct 2025 11:55:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today the closing of the transactions under the asset and share purchase agreement by and among the Company, Miza III Ventures Inc. and SciSparc Nutraceuticals Inc. (the “Agreement”). Pursuant to the Agreement, SciSparc rec</description>
    </item>
    <item>
      <title>SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/scisparc-ltd/news/scisparc-announces-closing-sale-n2off-200300425</link>
      <guid isPermaLink="true">https://6ix.com/company/scisparc-ltd/news/scisparc-announces-closing-sale-n2off-200300425</guid>
      <pubDate>Thu, 23 Oct 2025 20:03:00 GMT</pubDate>
      <description>TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the &quot;Company&quot; or &quot;SciSparc&quot;), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (Nasdaq: NITO) (“N2OFF”) of SciSparc’s majority owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”). MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by tar</description>
    </item>
  </channel>
</rss>